Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders
01. Februar 2023 09:05 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications
23. Januar 2023 09:02 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
16. August 2022 07:30 ET
|
Qualigen Therapeutics, Inc.
Q2 2022 FastPack ® Sales increased approximately 28%, and gross profit on product sales was up 64% year-over-year from Q2 2021 Milestone achievements in QN-302 and QN-247 oncology therapeutic...
Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex
02. Juni 2022 09:00 ET
|
Qualigen Therapeutics, Inc.
Transaction expected to significantly advance commercial readiness of NanoSynex’s innovative diagnostics technology platform focused on the $30+ Billion global infectious disease testing market ...
Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company NanoSynex
03. Mai 2022 09:17 ET
|
Qualigen Therapeutics, Inc.
Companies to Collaborate in the Development of Innovative Diagnostics Platform to Combat “Superbugs,” a Rising Global Health Crisis CARLSBAD, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Qualigen...
Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President
29. April 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics Resumes Worldwide Distribution and Commercial Control Over FastPack®
05. April 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
Company Prepared for Growth and Improved Profitability of its Diagnostics Business CARLSBAD, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified...
Qualigen Therapeutics CEO Michael Poirier Provides Letter to Shareholders
22. Februar 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics, Inc. Reports Third Quarter 2021 Financial Results
15. November 2021 09:00 ET
|
Qualigen Therapeutics, Inc.
Quarterly revenues increased 38% to approximately $1.2 million, compared to approximately $0.8 million in the same quarter of the previous yearYear-to-date revenues increased 30% to $4.2 million,...